Please share your phone number so we can contact you to learn about your health complaint.
Entresto (Sacubitril/Valsartan) is one of the most important modern treatments for chronic heart failure with reduced ejection fraction (HFrEF). By combining two active ingredients – Sacubitril and Valsartan – Entresto has revolutionized the management of heart failure, significantly reducing hospitalization rates and improving survival.
What is Entresto?
Entresto is a dual-action medication that contains:
Sacubitril: A neprilysin inhibitor that increases levels of natriuretic peptides, promoting vasodilation, sodium excretion, and reduced cardiac stress.
Valsartan: An angiotensin II receptor blocker (ARB) that lowers blood pressure and decreases strain on the heart.
This powerful combination helps improve heart efficiency, reduce symptoms, and enhance patients’ quality of life.
Indications
Entresto is prescribed for:
Treatment of chronic heart failure (HFrEF).
Reducing the risk of cardiovascular death and hospitalization.
Used as an alternative to ACE inhibitors or ARBs in eligible patients.
Administration and Dosage
Entresto is taken orally, twice daily.
The dose is determined by the physician, often starting low and increasing gradually.
Patients must stop ACE inhibitors at least 36 hours before starting Entresto to avoid complications.
Common Side Effects
Low blood pressure (hypotension) and dizziness.
Elevated potassium levels (hyperkalemia).
Impaired kidney function in some patients.
Dry cough (less common than ACE inhibitors).
Rarely, angioedema (swelling of face, lips, or throat).
Availability and Price in Egypt
Entresto in Egypt is available in various strengths. Its price is relatively high compared to other cardiovascular drugs, but its clinical benefits justify its widespread use in advanced heart failure management.
Conclusion
Entresto (Sacubitril/Valsartan) is a breakthrough therapy for heart failure, combining two mechanisms in one powerful drug. Despite its higher cost in Egypt, it remains an essential treatment for improving outcomes and survival among heart failure patients.
Contact the Macrocare team about starting treatment and booking a medical consultation.